Halozyme Therapeutics HALO Total debt

Total debt at other companies

West Pharmaceutical ServicesWST

$316.5M+2.7%

AMP

Amphastar PharmaceuticalsAMPH

$688.51M+5.0%

AptarGroupATR

$1.43B+32.7%

Opko HealthOPK

$49.94M-7.5%

Amneal Pharmaceuticals, Inc.AMRX

$2.57B+18.0%

Aquestive Therapeutics, Inc.AQST

$64.36M+7.4%

FAQ

What is Halozyme Therapeutics's total debt?

Halozyme Therapeutics (HALO) reported total debt of $2.18B in Q2 2026.

How has Halozyme Therapeutics's total debt changed year-over-year?

Halozyme Therapeutics's total debt increased by 41.6% year-over-year, from $1.54B to $2.18B.

What is the long-term trend for Halozyme Therapeutics's total debt?

Over 5 years (2020 to 2025), Halozyme Therapeutics's total debt has grown at a 40.2% compound annual growth rate (CAGR), from $402.1M to $2.18B.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.